Featured Research

from universities, journals, and other organizations

New Therapy Is Effective For Patients With Crohn's Disease, According To Studies

Date:
July 19, 2007
Source:
Mayo Clinic
Summary:
Researchers have found that Certolizumab pegol is an effective treatment for adults with Crohn's disease, according to two new studies. Crohn's disease is an inflammatory disorder of the gastrointestinal tract that affects an estimated 500,000 people in the United States. Symptoms include abdominal pain, fever, nausea, vomiting, weight loss and diarrhea.

Mayo Clinic researchers have found that certolizumab pegol is an effective treatment for adults with Crohn's disease, according to two new studies. These findings were published in the New England Journal of Medicine. Certolizumab pegol blocks tumor necrosis factor, an important cause of inflammation in Crohn's disease.

Related Articles


Crohn's disease is an inflammatory disorder of the gastrointestinal tract that affects an estimated 500,000 people in the United States. Symptoms include abdominal pain, fever, nausea, vomiting, weight loss and diarrhea. Crohn's disease has no known medical cure. Currently approved therapies that also block tumor necrosis factor include intravenous infusions of infliximab or subcutaneous injections of adalimumab.

"Many patients with Crohn's disease who receive repeated administration of infliximab or adalimumab will eventually stop responding to the therapy," says William Sandborn, M.D., a study author and gastroenterologist at Mayo Clinic. "Therefore, it is important to have a variety of options in this drug class to help patients avoid Crohn's disease symptoms over longer periods of time."

According to Dr. Sandborn, the dosing regimen for certolizumab pegol is more patient-friendly than infliximab or adalimumab, with less frequent subcutaneous injections that can be self-administered.

The first study, led by Dr. Sandborn, set out to determine if certolizumab pegol was effective in easing the symptoms of patients with active Crohn's disease. The study involved 662 adult patients with moderate to severe Crohn's disease, and represents a unique trial design in Crohn's disease. This is the first double-blind, placebo-controlled trial in which a drug that blocks tumor necrosis factor has been evaluated beyond 12 weeks in the treatment of Crohn's disease.

Researchers found that 35 percent of patients who received certolizumab pegol achieved an improvement in their clinical symptoms after six weeks, while 27 percent of patients who received a placebo experienced improved symptoms in the same period. Likewise, after six months, 37 percent of patients who received certolizumab pegol achieved an improvement in their clinical symptoms, compared to 27 percent of patients who received a placebo.

The second study set out to determine if certolizumab pegol was effective as a long-term maintenance therapy for patients with Crohn's disease. It involved 668 patients, of whom 428 (64 percent), responded, or achieved an improvement in their clinical symptoms, after taking certolizumab pegol for six weeks.

The response was maintained for six months in 63 percent of patients receiving certolizumab pegol, while 36 percent of patients who received a placebo from week six to six months experienced improved symptoms in that period. Additionally, clinical remission from symptoms was achieved in 48 percent of patients in the certolizumab pegol group, compared to 29 percent of those in the placebo group.

Certolizumab pegol is not yet approved by the Food and Drug Administration (FDA). One side effect of certolizumab pegol that was observed during the studies, and is seen in other drugs that block tumor necrosis factor, was a small increase in the risk for serious infection, including one case of pulmonary tuberculosis. However, injection-site reactions were very low and patients experienced low rates of antinuclear antibodies, which can occasionally cause lupus-like symptoms when elevated.

"Approximately 25 percent of the patients in these studies had previously been treated with infliximab therapy and had lost response," says Dr. Sandborn. "These studies show that certolizumab pegol could be a new option to treat patients with Crohn's disease, both those who have never been treated before, and those who have lost response to other therapies. Upon FDA approval, the use of certolizumab pegol could significantly improve quality of life for many patients with Crohn's disease."

Mayo Clinic is participating in ongoing clinical trials to examine the safety and effectiveness of using certolizumab pegol to treat Crohn's disease symptoms beyond six months. Each year, physicians at Mayo Clinic's campuses in Arizona, Florida and Minnesota treat approximately 2,000 patients who have Crohn's disease.

This research was funded by UCB Pharma, Inc. Mayo Clinic receives consulting fees from UCB Pharma, Inc. for work performed by Dr. Sandborn. Certolizumab pegol is a product of UCB Pharma, Inc.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "New Therapy Is Effective For Patients With Crohn's Disease, According To Studies." ScienceDaily. ScienceDaily, 19 July 2007. <www.sciencedaily.com/releases/2007/07/070719011358.htm>.
Mayo Clinic. (2007, July 19). New Therapy Is Effective For Patients With Crohn's Disease, According To Studies. ScienceDaily. Retrieved October 31, 2014 from www.sciencedaily.com/releases/2007/07/070719011358.htm
Mayo Clinic. "New Therapy Is Effective For Patients With Crohn's Disease, According To Studies." ScienceDaily. www.sciencedaily.com/releases/2007/07/070719011358.htm (accessed October 31, 2014).

Share This



More Health & Medicine News

Friday, October 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Melafind: Spotting Melanoma Without a Biopsy

Melafind: Spotting Melanoma Without a Biopsy

Ivanhoe (Oct. 31, 2014) The MelaFind device is a pain-free way to check suspicious moles for melanoma, without the need for a biopsy. Video provided by Ivanhoe
Powered by NewsLook.com
Battling Multiple Myeloma

Battling Multiple Myeloma

Ivanhoe (Oct. 31, 2014) The answer isn’t always found in new drugs – repurposing an ‘old’ drug that could mean better multiple myeloma treatment, and hope. Video provided by Ivanhoe
Powered by NewsLook.com
Chronic Inflammation and Prostate Cancer

Chronic Inflammation and Prostate Cancer

Ivanhoe (Oct. 31, 2014) New information that is linking chronic inflammation in the prostate and prostate cancer, which may help doctors and patients prevent cancer in the future. Video provided by Ivanhoe
Powered by NewsLook.com
Sickle Cell: Stopping Kids’ Silent Strokes

Sickle Cell: Stopping Kids’ Silent Strokes

Ivanhoe (Oct. 31, 2014) Blood transfusions are proving crucial to young sickle cell patients by helping prevent strokes, even when there is no outward sign of brain injury. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins